In contrast, hepatic overexpression of FDXR restored mitochondrial oxidation, increased TCA cycle activity, and alleviated steatosis in a mouse model, suggesting that therapeutic strategies aimed at enhancing FDXR activity could have significant potential in addressing MASLD. The gene discussed is FDXR; the disease is metabolic dysfunction-associated steatotic liver disease.